Rankings
▼
Calendar
▼
TLX FY 2016 Earnings Report — Telix Pharmaceuticals Limited Revenue & Financial Results | Market Cap Arena
Telix Pharmaceuticals Limited
TLX
FY 2016 Earnings
Reported December 30, 2016
Quarter Comparison
Revenue
Operating Income
EPS (Diluted)
Free Cash Flow
Metric
FY 2016
Prior Q
FY 2015
QoQ Change
YoY Change
Revenue
$0
—
$0
—
—
Op. Income
-$21.4K
—
-$82.9K
—
74.1%
EPS (Diluted)
$-0.00
—
$-0.00
—
81.3%
Free Cash Flow
$0
—
$0
—
—
marketcaparena.com
Income Statement
Item
Amount
REVENUE
$0
Cost of Revenue
$0
GROSS PROFIT
$0
R&D Expenses
$7.1K
Selling & Marketing
$0
General & Administrative
$14.3K
SG&A Expenses
$14.3K
Other Expenses
$0
Operating Expenses
$21.4K
Cost & Expenses
$21.4K
OPERATING INCOME
-$21.4K
Interest Income
$10.0K
Interest Expense
$0
Other Income/Expenses
-$10.0K
INCOME BEFORE TAX
-$31.4K
Income Tax Expense
$0
Net Income from Continuing Ops
-$31.4K
Net Income from Discontinued Ops
$0
Other Adjustments
$0
NET INCOME
-$31.4K
Net Income Deductions
$0
BOTTOM LINE NET INCOME
-$31.4K
D&A
$21.4K
EBIT
$0
EBITDA
-$10.0K
EPS
-$0
EPS Diluted
-$0
marketcaparena.com
Cash Flow Statement
Item
Amount
Net Income
-$31.4K
Depreciation & Amortization
$0
Stock-Based Compensation
$0
Deferred Income Tax
$0
Other Non-Cash Items
$31.4K
Change in Working Capital
$0
OPERATING CASH FLOW
$0
Capital Expenditure
$0
Acquisitions (Net)
$0
Purchases of Investments
$0
Sales/Maturities of Investments
$0
Other Investing Activities
$0
NET CASH FROM INVESTING
$0
Net Debt Issuance
$0
Common Stock Repurchased
$0
Common Dividends Paid
$0
Other Financing Activities
$0
NET CASH FROM FINANCING
$0
FREE CASH FLOW
$0
Net Change in Cash
$0
marketcaparena.com
← Q4 2015
TLX Overview
Q4 2017 →